Published in J Neurosci on August 04, 2010
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci (2012) 4.92
Soluble Aβ oligomer production and toxicity. J Neurochem (2011) 1.83
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol (2012) 1.05
Structural insights into Aβ42 oligomers using site-directed spin labeling. J Biol Chem (2013) 0.97
A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ. J Neurochem (2011) 0.95
Homeostatic disinhibition in the aging brain and Alzheimer's disease. J Alzheimers Dis (2011) 0.89
Conformational stability of fibrillar amyloid-beta oligomers via protofilament pair formation - a systematic computational study. PLoS One (2013) 0.88
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br J Pharmacol (2012) 0.84
A foldamer-dendrimer conjugate neutralizes synaptotoxic β-amyloid oligomers. PLoS One (2012) 0.84
Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. Transl Psychiatry (2013) 0.82
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain (2014) 0.81
On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity. Adv Bioinformatics (2012) 0.81
Oligomer-targeting with a conformational antibody fragment promotes toxicity in Aβ-expressing flies. Acta Neuropathol Commun (2014) 0.79
Structure-selective anisotropy assay for amyloid Beta oligomers. ACS Chem Neurosci (2012) 0.79
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms. Biomed Res Int (2013) 0.78
Preventive immunization of aged and juvenile non-human primates to β-amyloid. J Neuroinflammation (2012) 0.77
A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice. Sci Rep (2016) 0.77
Modeling amyloid-beta as homogeneous dodecamers and in complex with cellular prion protein. PLoS One (2012) 0.76
Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. Nat Commun (2016) 0.75
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? Immunotargets Ther (2013) 0.75
Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine. Hum Vaccin Immunother (2016) 0.75
The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. J Alzheimers Dis (2016) 0.75
Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. Int J Alzheimers Dis (2011) 0.75
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A (2007) 2.60
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest (2004) 2.52
Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry (2009) 2.31
A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther (2006) 2.06
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Cellular and network mechanisms underlying spontaneous sharp wave-ripple complexes in mouse hippocampal slices. J Physiol (2003) 1.76
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat (2006) 1.63
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res (2008) 1.61
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
The capsaicin receptor TRPV1 is a crucial mediator of the noxious effects of mustard oil. Curr Biol (2011) 1.56
Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain (2006) 1.55
Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci (2008) 1.54
Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta (2004) 1.47
Autoantibodies against cardiac troponin I in patients with congestive heart failure. Eur J Heart Fail (2010) 1.42
Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci (2006) 1.41
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther (2009) 1.40
A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med (2014) 1.39
Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J Neurosci (2011) 1.36
Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat (2004) 1.35
Dendritic transport and localization of protein kinase Mzeta mRNA: implications for molecular memory consolidation. J Biol Chem (2004) 1.34
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther (2005) 1.33
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther (2004) 1.33
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci (2007) 1.32
Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation (2013) 1.30
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol (2009) 1.29
Abeta-globulomers are formed independently of the fibril pathway. Neurobiol Dis (2008) 1.23
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry (2006) 1.16
Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci (2009) 1.15
mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology (2006) 1.15
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res (2010) 1.13
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem (2008) 1.10
Chronic stress-induced cellular changes in the medial prefrontal cortex and their potential clinical implications: does hemisphere location matter? Behav Brain Res (2008) 1.07
Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci (2008) 1.05
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta (2005) 1.03
Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea. Toxicon (2006) 1.03
Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology (Berl) (2006) 1.02
Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther (2006) 1.02
Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury. Brain Res (2004) 1.02
Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol (2005) 1.01
Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J (2011) 1.00
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther (2005) 0.99
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol (2008) 0.98
Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol (2005) 0.98
Ending aging in super glassy polymer membranes. Angew Chem Int Ed Engl (2014) 0.97
Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging (2010) 0.96
MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment. Mol Cancer (2010) 0.96
Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis (2005) 0.96
Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A (2004) 0.96
Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin Chem (2005) 0.94
Laser capture microdissection and microarray analysis of dividing neural progenitor cells from the adult rat hippocampus. Eur J Neurosci (2007) 0.94
Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology (Berl) (2007) 0.93
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev (2004) 0.93
Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects. Subcell Biochem (2005) 0.93
Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake. Psychopharmacology (Berl) (2008) 0.93
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem (2004) 0.92
Intravenous self-administration of abused solvents and anesthetics in mice. Eur J Pharmacol (2004) 0.92
C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke (2012) 0.91
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J Pharmacol Exp Ther (2002) 0.91
Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater (2015) 0.91
The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats. Eur J Neurosci (2004) 0.91
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther (2004) 0.91
Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther (2010) 0.89
Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest (2015) 0.89
Differential roles of telomere attrition in type I and II endometrial carcinogenesis. Am J Pathol (2008) 0.89
Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur J Pharmacol (2005) 0.89
Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J Pharmacol Exp Ther (2010) 0.89
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev (2003) 0.89
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther (2003) 0.88
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther (2012) 0.88
Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol Pharmacol (2008) 0.88
Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol (2006) 0.88
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem (2006) 0.88
Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors. Behav Pharmacol (2009) 0.87
YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol (2003) 0.87
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem (2008) 0.87
Development of disease-modifying treatment of schizophrenia. Handb Exp Pharmacol (2012) 0.86
Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neural Transm (Vienna) (2014) 0.85
Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs. Bioorg Med Chem Lett (2005) 0.85
Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. J Pharmacol Exp Ther (2004) 0.85
Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta (2008) 0.85
Selective factor XIIa inhibition attenuates silent brain ischemia: application of molecular imaging targeting coagulation pathway. JACC Cardiovasc Imaging (2012) 0.84
Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs). Bioorg Med Chem Lett (2002) 0.84
Absence of ApoE upregulates murine brain ApoD and ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels. J Alzheimers Dis (2009) 0.84